Symbols

SUPN

Supernus·NASDAQ

--(--)

SUPN fundamentals

SUPN Q4 2025 Earnings

Supernus (SUPN) released its earnings on Feb 24, 2026: revenue was 211.57M (YoY +21.48%), beat estimates; EPS was 0.8455 (YoY +13.28%), beat estimates.

Revenue / YoY

211.57M

+21.48%

EPS / YoY

0.8455

+13.28%

Report date

Feb 24, 2026

SUPN Earnings Call Summary for Q4,2025

Record Revenue Growth: 2025 total revenue of $719 million, with 76% from high-growth products.
ONAPGO Recovery: $17.3M first-year sales, supply constraints resolved, 700 patients in pipeline.
ZURZUVAE Momentum: 187% U.S. sales growth, 70% repeat prescribers, targeting women's health expansion.
2026 Outlook: $840-$870M revenue guidance, $45-$70M from ONAPGO, 20%-30% gross to net margin.
Pipeline Focus: Late-stage CNS assets and women's health opportunities for M&A.

Earnings

EPS

Revenue

Revenue & Expenses

SUPN has released its 2025 Q4 earnings report, with revenue of 211.57M, reflecting a YoY change of 21.48%, and net profit of -4.11M, showing a YoY change of -126.78%. The Sankey diagram below clearly presents SUPN's revenue sources and cost distribution.

Key Indicators

Supernus (SUPN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Supernus (SUPN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Supernus (SUPN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Supernus (SUPN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown